• Sponsored Content

RevIT™ AAV Enhancer: Rev-up AAV genome production in upstream manufacturing

BPI Contributor

February 16, 2024

1 Min Read
Mirus RevIT

The overall goal of gene therapies is to target common genetic diseases, which will require both localized and systemic application of AAV. In order to make this a reality, all components of the manufacturing process need to be evaluated and optimized to reduce cost-of-goods and increase the number of patient doses obtained per run. RevIT™ AAV Enhancer substantially increases AAV genome titers across multiple serotypes and transfection platforms, including the TransIT-VirusGEN® Transfection Reagent and polymeric transfection reagents. Simple optimization will allow for fast and easy integration of RevIT™ AAV Enhancer into existing AAV manufacturing workflows. These attributes, along with the ability to decrease the amount of pDNA, can lead to considerable savings in AAV-based gene therapy manufacturing costs.

You May Also Like